GE HealthCare Announces US Launch Of Longer Half-Life PET MPI Agent For Ischemia Detection

Flyrcado’s Long Half-Life And Stress-Test Compatibility Could Reshape Cardiac PET As GE HealthCare Targets 2026 For Its Photon-Counting CT Launch.

 
• By Shubham Singh

GE HealthCare is pursuing a dual-front imaging strategy with its PET MIP agent Flyrcado for detecting artery disease: It lasts longer than current PET scan tracers and allows patients to do treadmill-based stress tests alongside the scan.

Flyrcado’s CMS pass-through status, which lasts up to three years, ensures temporary reimbursement above the standard outpatient payment rate.
Key Takeaways
  • Flyrcado, GEHC’s new cardiac PET imaging agent, has CMS pass-through status, which lasts up to three years, ensures temporary reimbursement above the standard outpatient payment rate and is expected to generate $30m in 2025 and up to $500m by 2028.

GE HealthCare’s CEO has high expectations for Flyrcado, a positron emission tomography myocardial perfusion imaging (PET MPI) agent for detecting...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diagnostic Imaging

More from Medtech Insight

Ceryx Medical Amasses £11M To Develop Adaptive Cardiac Pacing Technology

 
• By Natasha Barrow

The Development Bank of Wales and London-based Parkwalk Advisors led an investment round of £5m, almost doubling Ceryx Medical's total investment to date.

SS Innovations’ SSI Mantra 3 Poised To Challenge Da Vinci In Robotic Surgery Market

 
• By Marion Webb

SS Innovations reported its first SSi Mantra 3 robotic cardiac surgery in South America as it prepares to file for US FDA de novo clearance and a CE mark. The firm aims to challenge Intuitive Surgical with a lower-cost, flexible system targeting US and European markets.

Innovative Wants Injunction Against J&J Subsidiary After $442M Antitrust Verdict

 
• By Elizabeth Orr

Innovative Healthcare is asking for a permanent injunction against Johnson & Johnson subsidiary Biosense Webster after winning a $442 million antitrust verdict. The injunction aims to prevent continued anticompetitive practices in the electrophysiology catheter market.